Lancaster JM - Search Results

1

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Among authors: lancaster jm. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

2

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays.

Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Berchuck A, et al. Among authors: lancaster jm. Am J Obstet Gynecol. 2004 Apr;190(4):910-25. doi: 10.1016/j.ajog.2004.02.005. Am J Obstet Gynecol. 2004. PMID: 15118612

3

Molecular aspects of ovarian cancer.

Wenham RM, Lancaster JM, Berchuck A. Wenham RM, et al. Among authors: lancaster jm. Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):483-97. doi: 10.1053/beog.2002.0298. Best Pract Res Clin Obstet Gynaecol. 2002. PMID: 12413930 Review.

4

An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.

Lancaster JM, Wiseman RW, Berchuck A. Lancaster JM, et al. Obstet Gynecol. 1996 Feb;87(2):306-9. doi: 10.1016/0029-7844(95)00405-X. Obstet Gynecol. 1996. PMID: 8559544

5

Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.

Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP. Berchuck A, et al. Among authors: lancaster jm. Clin Obstet Gynecol. 1998 Mar;41(1):157-66. doi: 10.1097/00003081-199803000-00022. Clin Obstet Gynecol. 1998. PMID: 9504233 Review. No abstract available.

6

Frequency of germline and somatic BRCA1 mutations in ovarian cancer.

Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, Deffenbaugh AM, Miron A, Marks JR, Futreal PA, Frank TS. Berchuck A, et al. Among authors: lancaster jm. Clin Cancer Res. 1998 Oct;4(10):2433-7. Clin Cancer Res. 1998. PMID: 9796975

7

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

8

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

9

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.

Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. Among authors: lancaster jm. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782

10

Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.

Lancaster JM, Cochran CJ, Brownlee HA, Evans AC, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. J Natl Cancer Inst. 1996 Apr 17;88(8):552-4. doi: 10.1093/jnci/88.8.552. J Natl Cancer Inst. 1996. PMID: 8606385 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page